Anda

Glenmark Pharma gets USFDA approval to manufacture generic version of hypertension drug Bystolic

According to IMS Health sales data for the 12 months to March 2017, the Bystolic tablets achieved annual sales of approximately $1 billion

Cipla gets USFDA nod for overactive bladder treating drug

Enablex tablets and generic equivalents had US sales of approximately $85 million for the 12 month period ending June 2016

RPG Life Sciences enters deal to acquire Sun Pharma's 7 brands

The move is in line with the company's strategy to focus on formulation business

Glenmark receives USFDA approval for anti-fungal ointment

According to IMS Health sales data for the 12 months to April 2016, Glenmark said Nystatin and triamcinolone acetonide ointment achieved annual sales of around $37.5 million

Glenmark's US arm receives US FDA approval for contraceptive tablets

Natco Pharma, partner clear patent case with Gilead, others over Tamiflu

In March last year, USFDA had granted tentative approval to Natco for the generic oseltamivir phosphate capsules

Glenmark gets tentative USFDA approval for Lacosamide tablets

Lacosamide Tablets is generic version of Vimpat Tablets of UCB Inc

Orchid Chemicals & Pharma zooms 16% in early trade on USFDA nod for generic drug

From its 52-week low level, the stock has so far gained a whopping 35 percent in last one week

Natco Pharma gains 4.5% after filing ANDA with USFDA

Natco Pharma has filed new product applications with the US health regulator for generic version of drugs used in the treatment of nervous system disease and cancer.

Cadila Healthcare Q3 profit rises 52% to Rs 282 cr

Drug firm Cadila Healthcare reported a 52 percent rise in its consolidated net profit to Rs 281.91 crore for the third quarter ended 31 December 2014 on back of robust sales.